FLT3 and acute myeloid leukemia: Quizartinib reduced the viability of the FLT3-ITD AML MV4-11, MOLM-13, and MOLM-14 cells, with IC50 values of 0.40, 0.89, and 0.73 nM, respectively (Supplementary Table 3).